BRIDGE PHARMA INC.

Patent Applications and Registrations

Patent applications and USPTO patent grants for BRIDGE PHARMA INC..The latest application filed is for "methods of treatment of inflammatory cytokine-related arthritic disorders".

Company Profile

4.43.29

BRIDGE PHARMA INC. - Sarasota FL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
Methods of treatment of asthma and COPD Grant 11,197,851 - Aberg , et al. December 14, 2	2021-12-14
Methods Of Treatment Of Inflammatory Cytokine-related Arthritic Disorders App 20210267960 - Aberg; A.K. Gunnar ; et al.	2021-09-02
Methods Of Treatment Of Asthma And Copd App 20210186945 - Aberg; A.K. Gunnar ; et al.	2021-06-24
Methods of treatment of asthma and COPD Grant 10,959,992 - Aberg , et al. March 30, 2	2021-03-30
Methods Of Treatment Of Asthma And Copd App 20200352927 - Aberg; A.K. Gunnar ; et al.	2020-11-12
Methods Of Treatment Of Respiratory Disorders App 20200268734 - Aberg; A.K. Gunnar ; et al.	2020-08-27
Medicinal Treatment of Chronic Inflammatory Dermal Disorders App 20180344721 - Aberg; A.K. Gunnar ; et al.	2018-12-06
Medicinal treatment of dermal infectious disorders with norketotifen Grant 9,808,419 - Aberg , et al. November 7, 2	2017-11-07
Formulations and methods for treating high intraocular pressure Grant 9,694,003 - Aberg , et al. July 4, 2	2017-07-04
Formulations and Methods for Treating High Intraocular Pressure App 20170105987 - Aberg; A.K. Gunnar ; et al.	2017-04-20
Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients Grant 9,439,895 - Aberg , et al. September 13, 2	2016-09-13
Methods Of Treating Pruritic Conditions Mediated Through Non-histaminergic Mechanisms In Diabetic Patients App 20160228426 - Aberg; A.K. Gunnar ; et al.	2016-08-11
Medicinal Treatment Of Dermal Infectious Disorders With Norketotifen App 20160193143 - ABERG; A. K. GUNNAR ; et al.	2016-07-07
Methods of treatment of non-histaminic pruritus Grant 9,345,697 - Aberg , et al. May 24, 2	2016-05-24
Methods of treatment of histamine H-4 receptor-related pruritus associated with nerve disorders Grant 9,333,199 - Aberg , et al. May 10, 2	2016-05-10
Methods Of Treatment Of Histamine H-4 Receptor-related Pruritus Associated With Nerve Disorders App 20150342944 - Aberg; A.K. Gunnar ; et al.	2015-12-03
Medicinal Treatment Of Chronic Pulmonary Inflammatory Diseases With Norketotifen App 20150272941 - Aberg; A. K. Gunnar ; et al.	2015-10-01
Methods Of Treatment Of Non-histaminic Pruritus App 20150272942 - Aberg; A.K. Gunnar ; et al.	2015-10-01
Methods of treatment of histamine H-4 receptor-related pruritus Grant 9,138,431 - Aberg , et al. September 22, 2	2015-09-22
Ocular formulations of norketotifen Grant 8,969,385 - Aberg , et al. March 3, 2	2015-03-03
Methods Of Treating Pruritic Conditions Mediated Through Histamine H-4 Receptors App 20150045392 - Aberg; A.K. Gunnar ; et al.	2015-02-12
Ocular Formulations Of Norketotifen App 20140303091 - Aberg; A.K. Gunnar ; et al.	2014-10-09
Medicinal treatment of dermal diseases in companion animals Grant 8,778,971 - Aberg , et al. July 15, 2	2014-07-15
Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen Grant 8,765,787 - Aberg , et al. July 1, 2	2014-07-01
Treating xerophthalmia with norketotifen Grant 8,741,930 - Aberg , et al. June 3, 2	2014-06-03
Medicinal Treatment Of Atopic Inflammatory Diseases App 20140120121 - Aberg; A.K. Gunnar ; et al.	2014-05-01
Medicinal Treatment Of Dermal Diseases In Companion Animals App 20140113936 - Aberg; A.K. Gunnar ; et al.	2014-04-24
Medicinal treatment of dermal diseases in dogs Grant 8,557,846 - Aberg , et al. October 15, 2	2013-10-15
Methods of accelerating muscle growth, decreasing fat deposits and improving feed efficiency in livestock animals Grant 8,445,542 - Aberg May 21, 2	2013-05-21
Methods Of Accelerating Muscle Growth, Decreasing Fat Deposits And Improving Feed Efficiency In Livestock Animals App 20130090295 - Aberg; A.K. Gunnar	2013-04-11
Use of RR/SR-ractopamine Grant 8,383,685 - Aberg February 26, 2	2013-02-26
Use Of RR/SR-Ractopamine App 20120015895 - Aberg; A.K.Gunnar	2012-01-19
Use of RR/SR-ractopamine Grant 8,071,653 - Aberg , et al. December 6, 2	2011-12-06
Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion App 20110294897 - Aberg; A.K. Gunnar ; et al.	2011-12-01
Formulations Of Indanylamines And The Use Thereof As Local Anesthetics And As Medication For Chronic Pain App 20110218218 - Aberg; A.K. Gunnar ; et al.	2011-09-08
Methods of accelerating muscle growth, decreasing fat deposits and improving feed efficiency in livestock animals Grant 7,985,775 - Aberg July 26, 2	2011-07-26
Optically active isomers of ketotifen and therapeutically active metabolites thereof Grant 7,872,025 - Aberg , et al. January 18, 2	2011-01-18
Use Of RR/SR-Ractopamine App 20100184865 - Aberg; A.K. Gunnar ; et al.	2010-07-22
S-Isomer of 2- piperidine and Other Dermal Anesthetic Agents App 20100179114 - Aberg; Gunnar ; et al.	2010-07-15
Ocular Formulations Of Norketotifen App 20100130550 - Aberg; A.K. Gunnar ; et al.	2010-05-27
Use of RR/SR-ractopamine Grant 7,723,392 - Aberg , et al. May 25, 2	2010-05-25
Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine Grant 7,718,674 - Aberg May 18, 2	2010-05-18
Optically active isomers of ketotifen and therapeutically active metabolites thereof Grant 7,557,128 - Aberg , et al. July 7, 2	2009-07-07
Formulations of Indanylamines and the Use Thereof as Local Anesthetics and as Medication for Chronic Pain App 20090137628 - Aberg; A.K. Gunnar ; et al.	2009-05-28
Methods for treating urinary incontinence in patients suffering from memory disorders Grant 7,390,816 - Aberg June 24, 2	2008-06-24
Methods of Accelerating Muscle Growth, Decreasing Fat Deposits and Improving Feed Efficiency in Livestock Animals App 20070282010 - Aberg; A.K. Gunnar	2007-12-06
Optically active isomers of ketotifen and therapeutically active metabolites thereof Grant 7,226,934 - Aberg , et al. June 5, 2	2007-06-05
Smooth muscle spasmolytic agents Grant 7,141,696 - Aberg , et al. November 28, 2	2006-11-28
R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics App 20060079558 - Aberg; Gunnar ; et al.	2006-04-13
S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics App 20060079559 - Aberg; Gunnar ; et al.	2006-04-13
Methods for treating urinary incontinence and other disorders using trospium Grant 6,974,820 - Aberg December 13, 2	2005-12-13
Non-arrhythmogenic metabolite of oxybutynin Grant 6,432,446 - Aberg August 13, 2	2002-08-13
Dermal anesthetic agents Grant 6,413,987 - Aberg , et al. July 2, 2	2002-07-02
Benzocycloheptathiophene compounds Grant 6,207,683 - Aberg , et al. March 27, 2	2001-03-27
Smooth muscle spasmolytic agents, compositions and methods of use thereof Grant 6,207,852 - Aberg , et al. March 27, 2	2001-03-27
Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use Grant 6,207,684 - Aberg March 27, 2	2001-03-27
Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin Grant 6,123,961 - Aberg September 26, 2	2000-09-26
Methods of accelerating muscle growth and improving feed efficiency in animals by using optically pure eutomers of adrenergic beta-2 receptor agonists, and food supplements containing the same Grant 6,110,974 - Aberg , et al. August 29, 2	2000-08-29

Company Registrations

NCAGE Code	5KW43	BRIDGE PHARMA INC.
CAGE Code	5KW43	BRIDGE PHARMA, INC.
DUNS	053444977	BRIDGE PHARMA, INC.

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.